{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:38:26Z","timestamp":1787315906904,"version":"build-2736575974"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T00:00:00Z","timestamp":1647475200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.vaccine.2022.03.013","type":"journal-article","created":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T09:02:09Z","timestamp":1648026129000},"page":"A85-A92","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"S1","title":["Analysis of population immunity to poliovirus following cessation of trivalent oral polio vaccine"],"prefix":"10.1016","volume":"41","author":[{"given":"Arend","family":"Voorman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hil","family":"Lyons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Bennette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Kovacs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeevan K.","family":"Makam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"F Vertefeuille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham","family":"Tallis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2022.03.013_b0005","series-title":"Polio eradication and endgame strategic plan 2013\u20132018","author":"Global Polio Eradication Initiative","year":"2013"},{"key":"10.1016\/j.vaccine.2022.03.013_b0010","unstructured":"World Health Organization. 14th meeting of the global commission for the certification of poliomyelitis eradication (GCC) Bali, Indonesia, 20\u201321 September, 2015: summary of findings, decisions and recommendations; 2015."},{"key":"10.1016\/j.vaccine.2022.03.013_b0015","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1093\/infdis\/jiw550","article-title":"A supply and demand management perspective on the accelerated global introductions of inactivated poliovirus vaccine in a constrained supply market","volume":"216","author":"Lewis","year":"2017","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2022.03.013_b0020","article-title":"Assessing and mitigating the risks for polio outbreaks in polio-free countries \u2014 Africa, 2013\u20132014","author":"Andre","year":"2014","journal-title":"Morb Mortal Wkly Rep"},{"issue":"48","key":"10.1016\/j.vaccine.2022.03.013_b0025","doi-asserted-by":"crossref","first-page":"5946","DOI":"10.1016\/j.vaccine.2016.10.017","article-title":"Measuring polio immunity to plan immunization activities","volume":"34","author":"Voorman","year":"2016","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2022.03.013_b0030","doi-asserted-by":"crossref","DOI":"10.1186\/1741-7015-12-92","article-title":"Predictive spatial risk model of poliovirus to aid prioritization and hasten eradication in Nigeria","volume":"12","author":"Upfill-Brown","year":"2014","journal-title":"BMC Med"},{"issue":"1","key":"10.1016\/j.vaccine.2022.03.013_b0035","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-017-0941-2","article-title":"Spatial model for risk prediction and sub-national prioritization to aid poliovirus eradication in Pakistan","volume":"15","author":"Mercer","year":"2017","journal-title":"BMC Med"},{"key":"10.1016\/j.vaccine.2022.03.013_b0040","doi-asserted-by":"crossref","unstructured":"Molodecky NA, Blake IM, Reilly KMO, Wadood MZ, Safdar RM, Wesolowski A, et al. Risk factors and short-term projections for serotype-1 poliomyelitis incidence in Pakistan: A spatiotemporal analysis; 2017. p. 1\u201319.","DOI":"10.1371\/journal.pmed.1002323"},{"issue":"1","key":"10.1016\/j.vaccine.2022.03.013_b0045","doi-asserted-by":"crossref","DOI":"10.1186\/s12879-017-2443-4","article-title":"An assessment of the geographical risks of wild and vaccine-derived poliomyelitis outbreaks in Africa and Asia","volume":"17","author":"O\u2019Reilly","year":"2017","journal-title":"BMC Infect Dis"},{"issue":"10","key":"10.1016\/j.vaccine.2022.03.013_b0050","doi-asserted-by":"crossref","first-page":"e1002140","DOI":"10.1371\/journal.pmed.1002140","article-title":"Population immunity against serotype-2 poliomyelitis leading up to the global withdrawal of the oral poliovirus vaccine: spatio-temporal modelling of surveillance data","volume":"13","author":"Pons-Salort","year":"2016","journal-title":"PLoS Med"},{"issue":"16","key":"10.1016\/j.vaccine.2022.03.013_b0055","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1056\/NEJMoa0803259","article-title":"Effectiveness of immunization against paralytic poliomyelitis in Nigeria","volume":"359","author":"Jenkins","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2022.03.013_b0060","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12916-016-0600-z","article-title":"Analysis of vaccination campaign effectiveness and population immunity to support and sustain polio elimination in Nigeria","volume":"14","author":"Upfill-Brown","year":"2016","journal-title":"BMC Med"},{"issue":"9840","key":"10.1016\/j.vaccine.2022.03.013_b0065","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(12)60648-5","article-title":"The effect of mass immunisation campaigns and new oral poliovirus vaccines on the incidence of poliomyelitis in Pakistan and Afghanistan, 2001\u201311: a retrospective analysis","volume":"380","author":"O'Reilly","year":"2012","journal-title":"The Lancet"},{"issue":"9570","key":"10.1016\/j.vaccine.2022.03.013_b0070","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1016\/S0140-6736(07)60531-5","article-title":"Protective efficacy of a monovalent oral type 1 poliovirus vaccine: a case-control study","volume":"369","author":"Grassly","year":"2007","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.vaccine.2022.03.013_b0075","doi-asserted-by":"crossref","first-page":"e90","DOI":"10.1016\/S2214-109X(13)70168-2","article-title":"Key issues in the persistence of poliomyelitis in Nigeria: a case-control study","volume":"2","author":"Mangal","year":"2014","journal-title":"Lancet Glob Heal"},{"issue":"9753","key":"10.1016\/j.vaccine.2022.03.013_b0080","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1016\/S0140-6736(10)61230-5","article-title":"Immunogenicity of bivalent types 1 and 3 oral poliovirus vaccine: a randomised, double-blind, controlled trial","volume":"376","author":"Sutter","year":"2010","journal-title":"Lancet"},{"issue":"10183","key":"10.1016\/j.vaccine.2022.03.013_b0085","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1016\/S0140-6736(19)30226-0","article-title":"Mapping diphtheria-pertussis-tetanus vaccine coverage in Africa, 2000\u20132016: a spatial and temporal modelling study","volume":"393","author":"Mosser","year":"2019","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.vaccine.2022.03.013_b0090","doi-asserted-by":"crossref","first-page":"e0107042","DOI":"10.1371\/journal.pone.0107042","article-title":"Disaggregating census data for population mapping using Random forests with remotely-sensed and ancillary data","volume":"10","author":"Stevens","year":"2015","journal-title":"PLoS ONE"},{"issue":"suppl_1","key":"10.1016\/j.vaccine.2022.03.013_b0095","doi-asserted-by":"crossref","first-page":"S333","DOI":"10.1093\/infdis\/jit816","article-title":"Lot quality assurance sampling to monitor supplemental immunization activity quality: an essential tool for improving performance in polio endemic countries","volume":"210","author":"Brown","year":"2014","journal-title":"J Infect Dis"},{"issue":"29","key":"10.1016\/j.vaccine.2022.03.013_b0100","doi-asserted-by":"crossref","first-page":"642","DOI":"10.15585\/mmwr.mm6829a3","article-title":"Progress toward poliomyelitis eradication \u2014 Nigeria, January 2018\u2013May 2019","volume":"68","author":"Adamu","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2022.03.013_b0105","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/163.1.1","article-title":"Mucosal immunity induced by enhance-potency inactivated and oral polio vaccines","author":"Onorato","year":"1991","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2022.03.013_b0110","article-title":"Real-time prediction model of cVDPV2 outbreaks to aid outbreak response vaccination strategies","author":"Voorman","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.03.013_b0115","unstructured":"WHO\/UNICEF Estimates of National Immunization Coverage, 2019 revision; 2020."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22002778?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22002778?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:25:42Z","timestamp":1759404342000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X22002778"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":23,"alternative-id":["S0264410X22002778"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.03.013","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Analysis of population immunity to poliovirus following cessation of trivalent oral polio vaccine","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.03.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}